EQS News: Marinomed Biotech AG announces results for the 2023 financial year and reports progress on Marinosolv and Carragelose assets

adminn

7 months ago

EQS News: Marinomed Biotech AG announces results for the 2023 financial year and reports progress on Marinosolv and Carragelose assets

EQS-News: Marinomed Biotech AG / Key word(s): Annual results Marinomed Biotech AG announces results for the 2023 financial year and reports progress on Marinosolv and Carragelose Assets April 16, 2024 / 07:45 CET/CEST The issuer is responsible for the content of the announcement / Editor responsible. ══════════════════════════════════════════════════ ═════════════════════════════════════════ Marinomed Biotech AG provides results for the 2023 financial year announced and reports progress at Marinosolv and Carragelose Assets • Sales in the 2023 financial year at EUR 9.2 million after record years due to the pandemic (2022: EUR 11.3 million) • Important progress at Carragelose with new sales partners and new products as well as improved stability at Marinosolv -Lead products • Outlook 2024 and beyond: The primary goal is to achieve operational profitability through the marketing of Carragelose and Marinosolv assets Korneuburg, Austria, April 16, 2024 – Marinomed Biotech AG (VSE:MARI) reports a decline in sales of 18, 6% to EUR 9.2 million (2022: EUR 11.3 million), which is well above pre-pandemic levels. The expected decline in demand for cough and cold products as the pandemic subsides, as well as high customer inventories, contributed to low order volume. Liquid assets decreased to EUR 2.6 million (2022: EUR 8.2 million), with no significant cash inflows contributing to the cash position in the 2023 financial year. In March 2024, Marinomed reached an agreement with the European Investment Bank to postpone the capital repayments of the 2019 venture loan (EUR 15 million) by 18 months. “In 2023, we made important progress on both Marinosolv and Carragelose. The challenges related to the stability of Budesolv and Tacrosolv have been largely resolved and the business development processes for both products have gained significant momentum. We have added two new products to the Carragelose portfolio and acquired new partners to fill white spots on the sales map. However, the commercialization of our Marinosolv products is taking longer than expected, so Marinomed is falling short of expectations,” comments Andreas Grassauer, CEO of Marinomed. “On the other hand, we have already reported good news in 2024: We recently launched new Carragelose products in Austria and Mexico, expanded our Carragelose network with two new partners and made important progress in market access in the US with P&G. At the same time, we are working intensively on partnering Budesolv and Tacrosolv.” Cost-conscious cash management The decline in sales was largely offset by savings in consulting costs and higher income from grants and funding. Research and development expenses remained almost unchanged at EUR 7 million (2022: EUR 6.9 million). The operating result (EBIT) was therefore EUR -5.1 million, slightly below the previous year’s value of EUR -4.9 million. The financial result was EUR -1.7 million (2022: EUR -1.5 million). The annual deficit therefore amounted to EUR -6.8 million, after EUR -6.4 million in 2022. Outlook for 2024 and beyond The growth of the Carragelose business will be driven by the support of new and existing partners in entering the market (e.g . B. with P&G in the USA or VitaPlus in Eastern Europe) as well as by concluding further partnerships for the new allergen-blocking nasal spray and the lubricating eye drops. At the same time, Marinomed is evaluating strategic options for the entire Carragelose portfolio. In the area of immunology, the focus is on concluding license agreements for Budesolv and Tacrosolv. Both products have been significantly improved in terms of stability and primary packaging, making them more attractive to potential partners. At the same time, the first partner for Budesolv, Luoxin, will be supported in reaching the next milestone. The current collaboration focuses on meeting regulatory and technical requirements as well as preparing a clinical trial in China. After several successful feasibility studies and smaller projects, the first long-term Solv4U partnership was concluded with SPH Sine in China in 2023. Similar partnerships are already emerging and could significantly increase Solv4U’s revenue contribution. “The recent agreement with the EIB and our property lenders to suspend repayments for 18 months gives us more flexibility to focus on commercializing our assets. In parallel, we are working on various initiatives that together have the potential to cover the company’s financing needs,” adds Pascal Schmidt, CFO of Marinomed. “Our primary goal is to achieve operational profitability. Our focus now is on near-term cash generation, including further licensing agreements for Budesolv and expanding our Carragelose business. We remain true to our mission to use our patented technologies to develop therapies for diseases with unmet medical needs, focusing on our Marinosolv platform – both with our own products and through Solv4U technology partnerships.” Selected financial indicators for the 2023 financial year All information in TEUR 2023 2022 Running 9,183.5 11,275.9 Personnel expenses -5.048.7 f & e expenses -7.032.9 -6.905.6 Operating result (EBIT) -5.129.2 -4 -4.6 ,794.7 EUR) -4.5 -4.3 equity -10,136.4 – 4,157.1 Balance total 14,611.7 22.286.6 Cashflow from the operating activity -4.5.202.9 Payment methods and payment -means equivalents 2.588.8 8.175.4 Total change of the payment methods and payment methods equivalents -5.586.5 2.373. Biotech AG is now available at 10 a.m. (CEST) about their years a telephone conference held in English. Andreas Grassauer, CEO, Eva Prieschl-Grassauer, CSO, and Pascal Schmidt, CFO, are available to discuss. To register, please follow this link: (1) https://www.c-meeting.com/web3/meetingRegistration/flaCLBqCy8FKUN6gMfcOmA/3DQVEEWL8KF8KV

Login conference call: After registering (see above), please use the information provided in the confirmation email to easily and quickly dial into the conference call. We recommend registering a few minutes before the conference starts. The presentation can be downloaded from the Company’s website approximately 15 minutes prior to the conference call: (2) https://www.marinomed.com/de/investoren-esg/finanzpublikationen

The 2023 Annual Results press release will be published on April 16, 2024 at 7:45 a.m. CEST / 6:45 a.m. BST and will be available in the News section of the Company’s website: (3) https://www.marinomed.com/de/news/corporate-news

The report is made available in the financial publications section: (4) https://www.marinomed.com/de/investoren-esg/finanzpublikationen

About Marinomed Biotech AG Marinomed Biotech AG is an Austrian, science-based biotechnology company with a growing development pipeline and globally marketed therapeutics. The company develops patent-protected, innovative products in the therapeutic areas of immunology and virology based on its Marinosolv® platform and the virus-blocking effect of Carragelose®. The Marinosolv® technology increases the solubility and bioavailability of poorly soluble active ingredients and is used to develop new therapeutics for indications in the area of autoreactive immune diseases. The Virology segment includes Carragelose®-based over-the-counter products for the prophylaxis and treatment of viral upper respiratory tract infections, partnered in more than 40 countries. The company is based in Korneuburg, Austria and is listed on the Prime Market of the Vienna Stock Exchange (VSE:MARI). Further information: (5) https://www.marinomed.com.

Inquiry note Marinomed Biotech AG International media inquiries PR & IR: Lucia Ziegler Metrum Communications: Eva Ruppnig T: +43 2262 90300 158 T: +43 664 4065744 E-mail: (6)pr@marinomed.com E-mail: (8)marinomed@metrum.at E-mail: (7)ir@marinomed.com Disclaimer This press release contains forward-looking statements that are based on current views, expectations and forecasts of the management of Marinomed Biotech AG about future events. These forward-looking statements are subject to risks, uncertainties and assumptions that could cause actual results, performance or events to differ materially from those described or otherwise expressed or implied by such statements. The current views, expectations and forecasts of the management of Marinomed Biotech AG are influenced by the context of such statements or words as “anticipate”, “believe”, “estimate”, “expect”, “intend”, “plan”, “project” and Recognize “target”. Forward-looking statements speak only as of the date on which they are made. Marinomed Biotech AG undertakes no obligation to update, revise or revise any forward-looking statements contained in this press release, whether as a result of new information, future developments or otherwise. Marinomed, Marinosolv® and Carragelose® are brands of Marinomed AG. The brands are the property of Marinomed Biotech AG or are licensed out to partners in selected countries. ══════════════════════════════════════════════════ ═════════════════════════════════════════ 16.04.2024 CET/CEST Publication of a corporate News/financial news, transmitted by EQS Group AG. www.eqs.com